Basic Information
TEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15MG/VIAL
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Regulatory Information
SIN16553P
July 18, 2022
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
June 3, 2025
XL01AC01
Company Information
Active Ingredients
Strength: 15mg/vial
Detailed Information
Contraindications
**4.3 Contraindications** Hypersensitivity to the active substance. Pregnancy and lactation (see section 4.6 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Concomitant use with yellow fever vaccine and with live virus and bacterial vaccines (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**4.1 Therapeutic indications** TEPADINA is indicated, in combination with other chemotherapy medicinal products: - with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients; - when high dose chemotherapy with HPCT support is appropriate for the treatment of breast cancer in adult patients and CNS tumours in paediatric patients.